Prostacyclin to prevent platelet activation during charcoal haemoperfusion in fulminant hepatic failure.
Adverse effects associated with hypotension and the appearance of platelet aggregates in the circulation complicate charcoal haemoperfusion of patients with fulminant hepatic failure. In an attempt to avoid these difficulties the platelet protective effect of prostacyclin (PGI2) given intravenously before and continuously during haemoperfusion was evaluated with an improved charcoal column design. Two of the six patients who underwent haemoperfusion without PGI2 had hypotension, which in one was associated with a striking rise in Swank screen filtration pressure necessitating discontinuation of haemoperfusion after an hour. No platelet losses were observed in the six patients treated with haemoperfusion and PGI2 infusion, and there was significant protection from platelet activation, as assessed by the prevention of release into plasma of the platelet-specific protein beta-thromboglobulin.
D000328:Adult; D001794:Blood Pressure; D002606:Charcoal / Q000627:therapeutic use; D004211:Disseminated Intravascular Coagulation / Q000517:prevention & control*; D011464:Epoprostenol / Q000008:administration & dosage / Q000627:therapeutic use; D006464:Hemoperfusion / Q000009:adverse effects* / Q000379:methods; D006501:Hepatic Encephalopathy / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007022:Hypotension / Q000517:prevention & control; D007263:Infusions, Parenteral; D010974:Platelet Aggregation / Q000187:drug effects*; D011465:Prostaglandins, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use*
D011465:Prostaglandins, Synthetic; D002606:Charcoal; D011464:Epoprostenol